Folate receptor alpha (FRα) is a protein found on the surface of certain cells that binds folic acid with extremely high affinity and pulls it inside. In healthy adults, it shows up in only a handful of tissues, but many cancers plaster it across their cell membranes in abundance, making it one of the more attractive targets in modern oncology. That dual life has turned FRα into a busy molecule in research: it is already the basis of an approved drug for ovarian cancer, an FDA-cleared fluorescent agent for surgical tumor detection, and a growing number of experimental immunotherapies and imaging tools.
What FRα Actually Is
FRα is a compact protein made up of about 204 amino acid residues arranged into a mix of helical and strand-like regions, held together by eight internal chemical bridges called disulfide bonds. It does not poke through the cell membrane the way most receptors do. Instead, it is tethered to the outer surface by a lipid anchor called a glycosylphosphatidylinositol (GPI) anchor, which essentially glues the protein to the fatty outer layer of the cell.1Journal of Chemical Theory and Computation. Characteristics of a Folate Receptor-α Anchored into a Multilipid Bilayer Obtained from Atomistic Molecular Dynamics Simulations That anchoring happens at a specific spot near the tail end of the protein, with one amino acid position strongly preferred as the attachment site.2PubMed. Preferred sites of glycosylphosphatidylinositol modification in folate receptors and constraints in the primary structure of the hydrophobic portion of the signal
The GPI anchor matters because it gives FRα unusual freedom of movement on the cell surface, and it means the receptor can be released from the membrane under certain conditions, producing a soluble form that ends up circulating in the blood. That soluble form turns out to be clinically useful, as discussed below.
Where FRα Appears in Healthy Tissue
In a normal adult body, FRα expression is surprisingly limited. The highest levels appear on the luminal (inner-facing) surfaces of certain epithelial tissues, such as the lining of the fallopian tubes and the proximal kidney tubules. In the fallopian tube, FRα is found almost exclusively in the columnar epithelium at relatively high levels, while the stromal tissue beneath is negative.3PubMed Central. Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers Normal ovarian tissue, by contrast, shows very low expression of FRα in either the epithelial or stromal layers.3PubMed Central. Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers
This restricted pattern is part of what makes FRα so attractive as a drug target. Because healthy tissues either do not express it or express it only on surfaces that are tucked away from the bloodstream, a therapy designed to home in on FRα is far less likely to damage normal cells. It is also worth noting that FRα is one member of a small family. Folate receptor beta (FRβ) has a different distribution, appearing mainly on activated immune cells rather than epithelial tissue, which opens a separate line of research entirely.
FRα in Early Development
Outside of cancer biology, FRα plays a critical role during embryonic development, particularly in the formation of the neural tube, the structure that becomes the brain and spinal cord. Studies in frog embryos have shown that knocking down the gene for FRα (called Folr1 in that species) impairs neural tube closure, producing neural tube defects in roughly 90% of affected embryos.4PubMed Central. Folate receptor 1 is necessary for neural plate cell apical constriction during Xenopus neural tube formation The defect appears to be specific to the process of neural plate folding rather than a general developmental problem: cells that lack FRα fail to constrict at their tops, preventing the plate from bending inward and closing properly.4PubMed Central. Folate receptor 1 is necessary for neural plate cell apical constriction during Xenopus neural tube formation
This finding aligns with the long-established link between folic acid supplementation during pregnancy and reduced rates of spina bifida and anencephaly. FRα appears to be the receptor through which folate exerts at least part of its protective effect on the developing nervous system, interacting with cell adhesion molecules to orchestrate the membrane remodeling needed for proper closure.
Overexpression in Cancer
The reason FRα dominates the oncology literature is that many epithelial cancers dramatically upregulate it. The strongest and most consistent overexpression occurs in ovarian cancer, especially in the high-grade serous subtype. In a cohort of 316 ovarian cancer patients, about 53% of tumors showed membrane or cytoplasmic FRα staining, and among those with high-grade serous histology, the positivity rate climbed to 60%.5British Journal of Cancer. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes No FRα expression was detected in matched normal tissues including fallopian tube, ovary, lung, kidney, and liver at a level comparable to tumor staining.5British Journal of Cancer. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
Lung cancer is the second major tumor type with notable FRα expression. Among non-small-cell lung cancers, adenocarcinomas show the highest rates: about 62% of adenocarcinomas tested positive in one study, compared with roughly 15% of squamous cell carcinomas.6PubMed Central. Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients Importantly, FRα expression tends to remain stable between the primary tumor and distant metastases, with concordance rates around 80% in lung cancer, which is encouraging for targeted therapies that need the target to persist as the disease spreads.6PubMed Central. Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients
In breast cancer, the picture is more variable. FRα positivity shows up in about half of primary tumors overall, but the subtype matters. Triple-negative breast cancers, the most aggressive subtype, express FRα at particularly high rates, with one study finding 85% of triple-negative tumors positive.7PubMed. Correlation of folate receptor alpha expression with clinicopathological parameters and outcome in triple negative breast cancer FRα expression in that subtype correlated with tumor grade and type, and served as a predictor of disease recurrence, though not overall survival.7PubMed. Correlation of folate receptor alpha expression with clinicopathological parameters and outcome in triple negative breast cancer Cervical cancer also shows a correlation: FRα protein levels increase alongside worsening lesion severity, and knocking down FRα in cervical cancer cells slows their growth.8PubMed. Folate receptor alpha is associated with cervical carcinogenesis and regulates cervical cancer cells growth by activating ERK1/2/c-Fos/c-Jun
How FRα Promotes Tumor Growth
FRα is not just a passive bystander that cancer cells happen to overproduce. Research over the past decade has shown that it actively participates in cancer-promoting signaling pathways, adding a mechanistic reason for tumors to keep it around. One striking finding is that FRα can move into the cell nucleus when folic acid is present, where it behaves like a transcription factor, directly binding to the regulatory regions of genes involved in growth, including the fibroblast growth factor receptor 4 gene (FGFR4). FRα’s presence significantly boosted activity of the FGFR4 gene promoter, and the effect increased further in the presence of folic acid.9Scientific Reports. Nuclear localization of folate receptor alpha: a new role as a transcription factor
Separately, FRα has been shown to activate STAT3, a well-known cancer-promoting signaling protein, through a pathway that involves the cell-surface molecule gp130 and enzymes called JAK kinases.10PubMed. Folic acid mediates activation of the pro-oncogene STAT3 via the Folate Receptor alpha In cervical cancer specifically, FRα drives tumor cell proliferation through the ERK signaling pathway: when researchers silenced FRα, levels of activated ERK, c-Fos, and c-Jun dropped, cell growth slowed, and apoptosis increased.8PubMed. Folate receptor alpha is associated with cervical carcinogenesis and regulates cervical cancer cells growth by activating ERK1/2/c-Fos/c-Jun Hormones add another wrinkle. The FRα gene promoter is repressed by estrogen and derepressed by the anti-estrogen drug tamoxifen in several carcinoma cell lines, meaning that the hormonal environment of a tumor can influence how much FRα is made.11Cancer Research. Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting
Mirvetuximab Soravtansine and the Antibody-Drug Conjugate Approach
The clearest clinical payoff from FRα research so far is mirvetuximab soravtansine, an antibody-drug conjugate (ADC) approved in the United States for platinum-resistant ovarian cancer. The drug works by coupling an antibody that recognizes FRα on the tumor cell surface with a potent cell-killing chemical called DM4. Once the antibody locks onto FRα, the whole complex is pulled inside the cell, broken down, and the toxic payload is released, destroying the cell from within. The released DM4 metabolites can also leak into neighboring cells, a phenomenon called bystander killing that helps reach tumor cells with lower FRα levels.12American Journal of Health-System Pharmacy. A review of mirvetuximab soravtansine-gynx in folate receptor alpha–expressing platinum-resistant ovarian cancer
The pivotal MIRASOL trial compared mirvetuximab to standard chemotherapy in patients whose tumors had high FRα expression. Median progression-free survival was about 5.6 months with mirvetuximab versus 4.0 months with chemotherapy, and overall survival was significantly longer at about 16.5 months versus 12.8 months. The response rate was 42% with mirvetuximab compared to 16% with chemotherapy.13The New England Journal of Medicine. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer An earlier single-arm study, SORAYA, had reported a response rate of about 32% and a median duration of response of nearly 7 months in a similar population.14PubMed Central. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Patient selection is essential. The drug’s benefit was demonstrated specifically in tumors where at least 75% of cells showed moderate-to-strong FRα membrane staining on a companion diagnostic test.15PubMed Central. Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker In the United States, this is assessed using a specific immunohistochemistry assay, but in the European Union, no single test is mandated, and pathology labs use a variety of antibodies, which has prompted quality-assurance studies to verify that different tests give comparable results.16PubMed Central. Results of the First Folate Receptor Alpha Testing Trial by the German Quality Assurance Initiative in Pathology (QuIP)
Surgical Imaging with Pafolacianine
FRα has also been harnessed for real-time tumor visualization during surgery. Pafolacianine is a fluorescent dye linked to a folate molecule: it binds to FRα-expressing tumor cells and lights up under near-infrared light, allowing surgeons to see cancer deposits that might be missed by the naked eye or by touch alone. The FDA approved it in late 2021 for use in ovarian cancer surgery.17PubMed Central. Intraoperative Tumor Detection Using Pafolacianine
A phase III trial showed that pafolacianine identified additional cancer tissue that was not planned for removal and was invisible under standard white-light inspection in about a third of patients. In patients undergoing interval debulking surgery, that figure rose to roughly 40%. Sensitivity for detecting ovarian cancer was 83%, though the patient-level false-positive rate was about 25%.18PubMed Central. A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006) The technology is not universal, however. A study evaluating pafolacianine in head and neck squamous cell carcinoma found it had limited utility because those tumors do not express enough FRα to produce adequate contrast between tumor and background tissue.19PubMed Central. Evaluation of Pafolacianine (Cytalux ® ) for Fluorescence-Guided Surgery in Head and Neck Squamous Cell Carcinoma: A Negative Study with Important Clinical Implications The lesson is straightforward: FRα-targeted imaging works well where FRα expression is high and fails where it is not.
Blood-Based Monitoring and PET Imaging
Because FRα can be shed from tumor cells into the bloodstream, researchers have investigated whether measuring soluble FRα (sFRα) in blood could track ovarian cancer noninvasively. Circulating sFRα levels are significantly higher in ovarian cancer patients than in healthy volunteers and correlate with how much FRα is present on the tumor itself. In patients receiving standard therapies, sFRα levels fell alongside shrinking tumor burden, suggesting the blood test tracks disease response in real time. Analysis showed that sFRα levels in treatment-naïve patients could distinguish those with a high tumor burden from those with a lower one with reasonable accuracy.5British Journal of Cancer. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes Other groups have found that sFRα outperformed the traditional ovarian cancer blood marker CA125 in distinguishing ovarian cancer from benign or borderline gynecological conditions, and that high sFRα levels were associated with shorter progression-free survival.20PubMed. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression
On the imaging side, researchers have been developing folate-based radiotracers for PET scanning, aiming to map FRα-positive tumors throughout the body without surgery. Most tracers have used fluorine-18 or gallium-68, though newer isotopes are under investigation. Only one folate-based PET agent has reached human patients so far, in a multicenter first-in-human trial for ovarian and lung cancer.21PubMed Central. Development of Folate Receptor-Targeted PET Radiopharmaceuticals for Tumor Imaging—A Bench-to-Bedside Journey The appeal is the same as with surgical imaging: if a scan can confirm FRα expression before treatment, clinicians could select the right patients for FRα-targeted drugs without relying solely on biopsies.
Resistance and Its Implications
As with any targeted therapy, resistance to FRα-directed drugs is a real and growing concern. Tumors can evade these treatments through several mechanisms. The most intuitive is antigen loss: tumors often express FRα unevenly, and cells with low or absent FRα can survive treatment and expand, eventually dominating the tumor. Altered cellular trafficking can also reduce the amount of drug payload that reaches its target inside the cell. And at the molecular level, some tumor cells upregulate drug-efflux pumps that actively push the toxic payload back out before it can do damage.22International Immunopharmacology. Folate receptor-α targeted therapies in ovarian cancer: recent advances and emerging therapeutic strategies
These overlapping escape routes mean that combination strategies and next-generation drug designs are under active investigation. Some approaches aim to pair FRα-targeted ADCs with immune checkpoint inhibitors or other agents that address the non-FRα-expressing tumor population. Others focus on improving the drug’s ability to kill bystander cells or on switching to payloads that are not substrates for drug-efflux pumps.
CAR T Cells Targeting FRα
Beyond ADCs, researchers are engineering immune cells to recognize and attack FRα-positive cancers. Chimeric antigen receptor (CAR) T cells built with an antibody fragment that locks onto FRα have shown potent tumor-killing ability in laboratory experiments. One group reported that FRα-directed CAR T cells destroyed more than 95% of target cells within 24 hours at higher effector-to-target ratios. In a mouse model, animals treated with these cells achieved 80% survival at 180 days, compared with 20% in the control group.23AACR Journals. Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma These results are preclinical, and CAR T cell therapies face well-known challenges in solid tumors, including difficulty penetrating dense tumor tissue and the immunosuppressive tumor microenvironment. Still, the strength of the preclinical signal keeps FRα on the short list of solid-tumor CAR T targets.
Cerebral Folate Deficiency
FRα’s importance is not confined to cancer. In the brain, it is expressed on the choroid plexus, the tissue responsible for producing cerebrospinal fluid and transporting nutrients, including folate, from the blood into the central nervous system. When this transport fails, the result is cerebral folate deficiency (CFD), a neurological condition that typically appears in early childhood. The most common cause is autoantibodies that block FRα on the choroid plexus: in a study of 28 affected children, 25 carried high-affinity blocking autoantibodies against the receptor, while none of 28 healthy controls did.24PubMed. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome Oral folinic acid, a form of folate that can partially bypass the blocked receptor, normalized folate levels in the cerebrospinal fluid and produced clinical improvement.24PubMed. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome
In rarer cases, CFD arises not from autoantibodies but from mutations in the FOLR1 gene itself.25PubMed Central. A Case of Cerebral Folate Deficiency due to FOLR1 Mutation in a 10-Year-Old Girl: Clinical Presentation and Treatment Outcomes Folate receptor autoantibodies have also been detected in a portion of children with autism spectrum disorder, prompting investigation into whether CFD may contribute to some cases of autism.26PubMed Central. Cerebral folate receptor autoantibodies in autism spectrum disorder That connection remains an active area of research, but it underscores how broadly FRα matters beyond its role in tumor biology.
Evolutionary Origins of the Folate Receptor Family
FRα did not appear out of nowhere. Phylogenetic analysis of the folate receptor gene family across vertebrates suggests that all current family members trace back to a single ancestral folate receptor gene. Ray-finned fish, lobe-finned fish, and snakes each carry a single folate receptor, while mammals ended up with three through lineage-specific duplications. One of those duplicates, Juno, migrated to a new chromosomal location early in mammalian evolution and took on a completely different function: it became the egg-surface receptor that is essential for sperm-egg fusion during fertilization.27PubMed Central. Izumo1 and Juno: the evolutionary origins and coevolution of essential sperm–egg binding partners In other words, a folate receptor duplicate was repurposed into one of the most critical molecules in mammalian reproduction. Birds, alligators, and turtles had their own independent duplications of the ancestral gene, producing additional copies in different chromosomal neighborhoods. The overall picture is a small gene family that has been recycled and reinvented repeatedly throughout vertebrate evolution, with FRα retaining the original folate-binding function and its relatives branching into roles that have nothing to do with vitamins at all.